|Bid||2.43 x 100|
|Ask||2.50 x 100|
|Day's Range||2.43 - 2.49|
|52 Week Range||2.20 - 3.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Since Celldex Therapeutics Inc (NASDAQ:CLDX) released its earnings in December 2017, analyst consensus outlook seem pessimistic, as a -27.84% fall in profits is expected in the upcoming year. Though thisRead More...
Celldex (CLDX) reports narrower-than-expected loss in Q4 with sales also beating estimates. Moreover, shares rise in after-hours trading on Mar 7 following the results.
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / U.S. markets slumped Wednesday after Gary Cohn, President Trump's top economic advisor, announced his resignation. The Dow Jones Industrial Average hit a low ...
On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 3 cents. Losses, adjusted for pretax gains and non-recurring gains, were 17 cents per share. The results exceeded Wall ...
HAMPTON, N.J., March 07, 2018-- Celldex Therapeutics, Inc. today reported business and financial highlights for the fourth quarter and year ended December 31, 2017. The Company will host a conference call ...
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Celldex Therapeutics, Inc. (NASDAQ: CLDX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at 4:30 PM Eastern ...
Merck's (MKGAF) Healthcare and Life Science segments are likely to drive sales in Q4. However, the company's oncology drug fails in a phase III gastric cancer study.
HAMPTON, N.J., March 02, 2018-- Celldex Therapeutics, Inc. announced today upcoming investor events in March.. 2017 Year-End Results and Conference Call/Webcast. Celldex will release fourth quarter and ...
A small biotech, a Chinese tech giant, and the world's biggest coffee seller may be surprising choices to outgain Tesla. Keep reading to learn why they're on track to be better investments.
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Workday, ...
After a decades-long journey, 2018 could be the year Celldex Therapeutics transitions from a clinical-stage biotech to one with a product to sell.
Shopify has been a solid growth vehicle for investors, but these three stocks might be even better picks going forward.
Ultragenyx (RARE) announces data from phase I/II study on its AAV gene therapy candidate, DTX301, demonstrating normalization of ureagenesis in patients with ornithine transcarbamylase deficiency.